Abstract. Extraskeletal myxoid chondrosarcoma (ESMC) of the vulva is an extremely rare tumor and currently, there is little available information on its biological behavior and treatment strategy. The present study reports a case of recurrent ESMC of the vulva in a 32-year-old female. The patient presented with an increasingly painful mass of the right vulva, at the site of an excision which had been performed 7-months previously. The tumor mass was histopathologically diagnosed as primary ESMC of the vulva and subsequently, vulvectomy was performed. Cytological examination showed negative surgical margins. Intraoperative radiation therapy at a single dose of 10 Gy was administered to the bed of the removed tumor. The patient refused chemotherapy and five months after surgery, a new lesion was identified in the inguinal region. Bilateral inguinal-femoral lymph node dissection was performed and external beam radiation therapy at a dose of 40 Gy was administered to the inguinal region. Follow-up examination seven months after surgery revealed no evidence of disease progression and at present, the patient remains alive. This study highlights the importance of analyzing each clinical case of ESMC as this may lead to the development of guidelines for the optimal treatment of this rare tumor.

Introduction

Approximately 90% of all malignant tumors of the vulva are squamous cell carcinomas. Sarcomas of the vulva constitute a variety of malignant neoplasms that account for 1-2% of vulvar cancers (1,2); the most common are rhabdomyosarcoma, leiomyosarcoma, epithelioid sarcoma, alveolar sarcoma of the soft tissues and liposarcoma (3).

In accordance with the 2013 World Health Organization (WHO) histological classification of tumors (4), sarcomas are classified into soft-tissue tumors and subclassified into malignant soft-tissue tumors. Extraskeletal myxoid chondrosarcoma (ESMC) represent <3% of all soft-tissue sarcomas (5).

Stout and Verner first described ESMC in 1953 (6). In 1994, ESMC was included into the group of soft-tissue tumors with uncertain differentiation (7).

ESMC has a male to female ratio of 2:1, with the peak occurrence in the sixth decade of life (8). ESMC is more commonly observed in the lower extremities, however, cases of ESMC of the orbit, shoulder and upper extremities have been reported (7,9,10-17). The majority of these tumors are solitary, deeply-seated, superficial, slowly-growing nodules, measuring 5-10 cm in diameter. The lesions are typically well-circumscribed and have a gelatinous appearance, often with hemorrhagic foci (18).

Light microscopic examination reveals the presence of rather monomorphic, small, round or oval cells with centrally located hyperchromic or vesicular nucleus, with evenly distributed chromatin, scant eosinophilic cytoplasm and often no evident nucleolus. Cells form straight or bent linear chains anastomosing between each other and forming a lacy arcade pattern. Perivascular condensation of the tumor cells, with formation of pseudorosettes, also occurs. Tumor structures are located in the prominent basophilic myxoid slightly vascular matrix. The tumor is divided into small lobules by narrow fibrous septa of different thicknesses. The peripheral region of the tumor is characterized by high cellularity, often with the evidence of rhabdoid and epithelioid cells. Cysts, hemorrhages and geographic necroses can occur in the tumor tissues (7,19-23).

Irrespective of ESMC localization, pre-operative diagnosis may be difficult, and thus verification is carried out based on the results of core-biopsy, followed by the evaluation of immunohistochemical and histological changes in the tumor tissue (24).

Correspondence to: Dr Alisa Villert, Department of Oncogynecology, Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, 5 Kooperativny Street, Tomsk 634050, Russia

E-mail: avillert@yandex.ru

Key words: vulvar cancer, extraskeletal myxoid chondrosarcoma, diagnostics, treatment, prognostic factors
has been reported to elicit only a poor response (26). Radiation therapy is recommended for high-grade sarcomas, moderately-differentiated tumors, positive surgical margins and recurrent sarcoma (27-29). The two drugs with the highest established response rates in soft-tissue sarcoma are doxorubicin and ifosfamide, and this drug combination has been used as the gold standard for a number of years. However, this chemotherapy schedule has been found to be ineffective for ESMC (30). Interferon α-2b has been investigated in several studies, showing promising results (31). Gemcitabine, methotrexate and imatinib can also be administered for this type of tumor in an adjuvant regimen (32). In 2010, a study by Geyer and Karlin reported that there were no studies showing the efficiency of the modern chemotherapy regimens for ESMC (33). Adjuvant radiation therapy for ESMC is used prior to chemotherapy in cases with positive surgical margins and in cases where it is impossible to perform a resection (32).

ESMC has been described as slowly growing and late to metastasize. Due to the rarity, protracted clinical course and prolonged survival of patients with ESMC, long-term follow-up is recommended for the early detection of local recurrence and distant metastases. ESMC has been reported to have a relatively good prognosis. However, ESMC has a high potential for metastasis, particularly to the lungs, regional lymph nodes and bones (21,34-36). Enzinger and Shiraki considered that neither the tumor localization nor the tumor size affected the disease prognosis, however, the study underlined the fact that the prognosis is associated with the histological grade (9). A more recent study by Oliviera et al defined high cellularity, large tumor size, presence of anaplasia or rhabdoid features, high mitotic activity (≥2 per 10 high-power fields) and proliferative activity (Ki-67, ≥10%; Ki-67 ‘hot spot’, ≥25%) as adverse prognostic factors (37). Meis-Kindblom et al analyzed 117 cases with ESMC and showed that the clinical parameters, but not the histological features, were associated with decreased survival (35).

The overall 5-, 10-, and 15-year survival rates of patients with ESMC are reported to be 82-90, 63-70 and 58%, respectively. Two-thirds of patients develop recurrences and more than half of the patients develop metastases. Local recurrences are observed in 48% of cases (half of these are multiple local recurrences) and metastatic recurrences are observed in 46% of cases (26,32,35).

The present study reports a case of recurrent ESMC of the vulva in a 32-year-old female. Written informed consent was obtained from the patient.

Case report

In June 2011, a 32-year-old female presented to a gynecological clinic (Lensk, Russia) with a painful lesion on the right vulva arising after a trauma. Ultrasound examination revealed a round hypovascular mass, measuring 53x34x37 mm, in the soft tissues of the vulva. The patient underwent surgical excision of the mass. The conclusive diagnosis of the surgical specimen was of an organized hematoma.

A mass that was gradually increasingly painful was observed at the site of the excision at 7 months post-surgery. The patient was then referred to the Cancer Research Institute (Siberian Branch of the Russian Academy of Medical Sciences, Tomsk, Russia).

Gynecological examination revealed a tumor mass in the upper and middle thirds of the right labia majora, with involvement of the pubic area. The lesion consisted of multiple nodules with uneven density and well-defined borders, and was painful when palpated.

Histological analysis showed a spindle-like cell sarcoma [G2 (4)]. Examination of the tumor tissue revealed small monomorphic cells with scant eosinophilic cytoplasm. Tumor cells formed straight or linear chains and exhibited anastomosis, forming an arcade pattern. The tumor structures were located in the prominent basophilic myxoid with a slightly vascular matrix. Hemorrhage and geographic necrosis were also evident in the tumor tissue.

The ultrasonographic findings revealed a dumbbell-shaped lesion measuring 27x70 mm, with a heterogeneous structure, sharp and smooth contour.
Spiral computed tomography scan revealed a well-defined multiple nodular lesion of soft-tissue density, actively accumulating the contrast, which was located in the soft tissues at the level of the symphysis pubis, on the right-hand side. The tumor extended to the right labia majora. Surrounding cellular tissue was thickened, but adjacent bone structures were unchanged. There was no evidence of lymph node involvement and no metastases were revealed.

No pathological changes were noted in the abdomen or chest.

The patient underwent wide excision of the tumor with reconstructive plastic surgery using local tissue flaps. The tumor was removed through a vertical incision. Cytological examination showed negative surgical margins. Intraoperative radiation therapy (IORT) at a single dose of 10 Gy was delivered to the bed of the removed tumor (Fig. 1). The wound was the closed layer by layer. There were no complications in the post-operative period.

Macroscopic imaging of the surgical specimen showed a tumor with multiple nodules, measuring 5 cm at its widest, which was mainly of elastic consistency, with a well-defined fibrotic capsule, and with areas containing gelatinous material and hemorrhages (Fig. 2).

A pathological study of this case revealed that the tumor was circumscribed by a pseudocapsule and consisted mainly of moderately polymorphic spindle-shaped cells and to a lesser extent, epithelioid cells, with swollen or prolate nuclei, vesicular chromatin, with one hypertrophic hyperchromic nucleolus and with bipolar amphophilic cytoplasmic processes. Cells formed syncytial, clustered and lacy structures immersed in the abundant myxoid matrix, with mild diffuse lymphoid infiltration. Fields of rhabdoid cells and foci of necrosis were observed within the tumor. A few atypical multinucleated giant cells were also present. Moderate mitotic activity with the presence of pathology forms was noted. The tumor tissue, mainly in peripheral areas, was divided into fields by fibrous bands with mild diffuse infiltration (Fig. 3). The majority of the tumor cells expressed neuron-specific enolase (monoclonal anti-human mouse antibody; clone BBS/NC1/A-H14; 1:600; Dako, Glostrup, Denmark) (Fig. 4). S-100 (monoclonal anti-human rabbit antibody; 1:600; Dako) was weakly expressed in the nuclei of certain cells. No expression was detected for pan-cytokeratin (monoclonal anti-human mouse antibody; 5/6/8/18; clones 5D3 and LP34; 1:100; Leica Biosystems, Wetzlar, Germany), muscle actin (monoclonal anti-human mouse antibody; clone 1A4; 1:100; Dako), cluster of differentiation 34 (monoclonal anti-human mouse antibody; clone QBE8 10; 1:100; Dako), desmin (monoclonal anti-human mouse antibody; clone DE-R-11; 1:100; Dako), MyoD1 (monoclonal anti-human mouse antibody; clone 5.8A; 1:140; Dako) and synaptophysin (monoclonal anti-human mouse antibody; clone SY38; 1:200; Dako). The proliferative activity of the tumor was high, with a Ki-67 of 26%.

The histological structure and immunophenotype of the tumor cells demonstrated an ESMC, G2 (4). Soft-tissue sarcoma of the vulva, stage Ib (T1bN0M0) was diagnosed.

The patient refused chemotherapy. A new lesion appeared in the right inguinal region 5 months after the surgery for recurrent vulvar cancer.

Magnetic resonance imaging showed heterogeneous enhancement of enlarged lymph nodes, measuring 37x25x34 mm, in the right inguinal region. Cytological examination revealed sarcoma cells. Due to disease progression, a bilateral inguinal-femoral lymph node dissection was performed. Metastatic involvement of ESMC in 1 of 13 lymph nodes was histologically confirmed. The patient subsequently received 40 Gy external beam radiation therapy to the inguinal region. The patient is currently alive with no evidence of disease progression at the 7 month follow-up.

Discussion

ESMC of the vulva is an extremely rare malignant neoplasm. Only 4 clinical cases have been reported in the literature to date (38-41). The first clinical case was described in 1996, where the diagnosis of ESMC was established in a 40-year-old female with a tumor in the left labium majus. Following a wide excision of the vulvar tumor and inguinal lymphodissection, the patient was followed up for 40 months with no evidence of recurrence (39). The second clinical case of ESMC occurred...
in a 46-year-old female and was published in 2005 (40). In two recent studies (2011), the patients were aged 24 and 66 years (38,41). In the 24-year-old female, the histological diagnosis was established only after total biopsy. The patient underwent vulvectomy with vulvoperineal reconstruction. Microscopic examination of the resected specimens revealed ESMC tumor nodules. However, no viable tumor cells were present at the surgical margin. The duration of recurrence-free follow-up was 2 years (41). The ESMC case of the 66-year-old patient was notable due to a prolonged postmenopausal period (20 years), large tumor size (8x12 cm) and combination treatment involving complete removal of the tumor and adjuvant radiation therapy. There was no evidence of recurrence after 1 year of follow-up (38).

There is little comparative data supporting the superiority of specific treatment regimens due to the low incidence of the ESMC.

In the present clinical case, ESMC was diagnosed too late for antitumor treatment to be effective. Improvement of optical imaging techniques, including histochemical methods, can contribute to the early diagnosis of ESMC of the vulva (9).

Due to the absence of a unified approach to the treatment of recurrent tumors, intraoperative radiation therapy to the bed of the removed tumor was selected in the present study, although there have been no studies regarding the efficiency of IORT for vulvar sarcomas, including ESMC.

In spite of the obscure pathogenesis and absence of a pathogenetically proven therapeutic strategy for vulvar sarcomas, including ESMC of the vulva, the analysis of each clinical case has a high value and can contribute to the development of the optimal treatment policy.

References

1. Bodurka DC and Gershenson DM: Sarcomas of reproductive tract. Atlas Clin Oncol Soft Tissue Sarcomas 15: 213-227, 2002.
2. Tavassoli FA and Norris HJ: Smooth muscle tumors of the vulva. Obstet Gynecol 53: 213-217, 1979.
3. Korzhaevskaya VV, Kuznetsov VV and Gritsay AH: Sarcomas of the vulva. Sib Onkol Zh 2: 10-14, 2008 (In Russian).
4. Lucas DR and Stemmer-Corradin R: Tumours of uncertain differentiation. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Bridge JA, Hogendoorn PCW and Mertens F (eds). 4th edition. IARC Press, Lyon, pp223-224, 2013.
5. Tsuneyoshi M, Enjoji M, Iwashaki H and Shinohara N: Extraskeletal myxoid chondrosarcoma - a clinicopathologic and electron microscopic study. Acta Pathol Jpn 31: 439-447, 1981.
6. Stout AP and Verner EW: Chondrosarcoma of extraskeletal soft tissues. Cancer 6: 581-590, 1953.
7. Lucas DR and Heim S: Tumours of uncertain differentiation. In: Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Bridge JA, Hogendoorn PCW and Mertens F (eds). 4th edition. IARC Press, Lyon, pp184-224, 2002.
8. Hachitanda Y, Tsuneyoshi M, Daimaru Y, Enjoji M, Nakagawara A, Ikeda K and Sueishi K: Extraskeletal myxoid chondrosarcoma in young children. Cancer 61: 2521-2526, 1988.
9. Enzinger FM and Shiraki M: Extraskeletal myxoid chondrosarcoma. An analysis of 34 cases. Hum Pathol 3: 421-435, 1972.
10. Fukuda T, Ishikawa H, Ohnishi Y, Tachikawa S, Onizuka S and Sakashita I: Extraskeletal myxoid chondrosarcoma arising from the retroperitoneum. Am J Clin Pathol 85: 514-519, 1986.
11. Gaudier F, Khurana JS, Dewan S and Shen T: Fine-needle aspiration cytology of intra-abdominal wall extraskeletal myxoid chondrosarcoma: a case report and review of the literature. Arch Pathol Lab Med 127: 1211-1213, 2003.
12. Goetz SP, Robinson RA and Landas SK: Extraskeletal myxoid chondrosarcoma of the pleura. Report of a case clinically simulating mesothelioma. Am J Clin Pathol 97: 498-502, 1992.
13. Khouja N, Ben Amor S, Jemel H, Kchir N, Boussen H and Khalidi M: Mesenchymal extraskeletal chondrosarcoma of the orbit. Report of a case and review of the literature. Surg Neurol 52: 50-53, 1999.
14. Kilpatrick SE, Inwards CY, Fletcher CD, Smith MA and D’Cruz S: Myxoid chondrosarcoma (chondroid sarcoma) of bone: a report of two cases and review of the literature. Cancer 79: 1903-1910, 1997.
15. Okamoto S, Hisaoka M, Ishida T, Imamura T, Kanda H, Shimajiri S and Hashimoto H: Extraskeletal myxoid chondrosarcoma: A clinicopathologic, immunohistochemical, and molecular analysis of 18 cases. Hum Pathol 32: 1116-1124, 2001.
16. Sato K, Kubota T, Yoshida K and Murata H: Intracranial extraskeletal myxoid chondrosarcoma with special reference to lamellar inclusions in the rough endoplasmic reticulum. Acta Neuropathol 86: 525-528, 1993.
17. Sato N, Minase T, Yoshida Y, Narimatsu E, Muroya K, Asaiishi K and Kikuchi K: An ultrastructural study of extraskeletal myxoid chondrosarcoma. Acta Pathol Jpn 34: 1355-1363, 1984.
18. Hisaoka M and Hashimoto H: Extraskeletal myxoid chondrosarcoma: updated clinicopathological and molecular genetic characteristics. Pathol Int 55: 453-463, 2005.
19. Goldblum JR: The series foundations in diagnostic pathology. In: Bone and Soft Tissue Pathology. Folpe AL and Inwards CY (eds). Saunders Elsevier, Philadelphia, p462, 2010.
20. Mavrogenis AF, Patapis P, Papaparaskeva KT, Galanis EC and Papagelopoulos PJ: Extraskeletal myxoid chondrosarcoma of the perineum. Orthopedics 32: 216, 2009.
21. Bleyl SB, Walker LA, Wilson RM Jr, Kransdorf MJ, Temple HT and Gannon FH: From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. Radiographics 23: 1245-1278, 2003.
22. Weiss SW and Goldblum JR: Cartilaginous soft tissue tumors. In: Enzinger and Weiss’s Soft Tissue Tumors. 5th edition. Mosby Elsevier, China, pp1017-1038, 2008.
23. Horn LC, Werschnik C, Bilek K and Emmert C: Diagnosis and clinical management in malignant Müllerian tumors of the fallopian tube. A report of four cases and review of recent literature. Arch Gynecol Obstet 258: 47-53, 1996.
24. Ananthamurthy A, Nisheena R, Rao B and Correa M: Extraskeletal myxoid chondrosarcoma: Diagnosis of a rare soft tissue tumor based on fine needle aspiration cytology. J Cytol 26: 36-38, 2009.
25. ESMO/European Sarcoma Network Working Group: Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 (Suppl 3): S102-S112, 2014.
26. McGory JE, Rock MG, Nascimento AG and Oliveira AM: Extraskeletal myxoid chondrosarcoma. Clin Orthop Relat Res 464: 182-191, 2006.
27. Mccarter MD, Jaques DP and Brennan MF: Randomized clinical trials in soft tissue sarcoma. Surg Oncol Clin N Am 11: 11-22, 2002.
28. Reed NS, Mangioni C, Malmstrom H, et al: European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group: Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44: 808-818, 2008.
29. Wylie JP, O’Sullivan B, Catton C and Gutierrez E: Contemporary radiotherapy for soft tissue sarcoma. Semin Surg Oncol 17: 33-46, 1999.
30. Patel SR, Burgess MA, Papadopoulos NE, Linke KA and Benjamin RS: Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy. Am J Clin Oncol 18: 161-163, 1995.
31. Rubinger M, Penderleith IH, Lertzman M and Worth AJ: Metastatic extraskeletal myxoid chondrosarcoma. Successful therapy with interferon alfa-2b. Chest 108: 281-282, 1995.
32. Orion AD, Poput S, Bhuchar G, et al: Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. Cancer 113: 3364-3371, 2008.
33. Geyer HL and Karlin N: Extraskeletal myxoid chondrosarcoma of the heart and review of current literature. Curr Oncol 17: 58-62, 2010.
34. Gracia I, Major J, Peiró A and Doncel A: Extraskeletal bone sarcomas. The Internet Journal of Orthopedic Surgery 3: 2005.
35. Meis-Kindblom JM, Bergh P, Gunterberg B and Kindblom LG: Extraskeletal myxoid chondrosarcoma: A reappraisal of its morphologic spectrum and prognostic factors based on 117 cases. Am J Surg Pathol 23: 636-650, 1999.

36. Saleh G, Evans HL, Ro JY and Ayala AG: Extraskeletal myxoid chondrosarcoma. A clinicopathologic study of ten patients with long-term follow-up. Cancer 70: 2827-2830, 1992.

37. Oliveira AM, Sebo TJ, McGrory JE, Gaffey TA, Rock MG and Nascimento AG: Extraskeletal myxoid chondrosarcoma: A clinicopathologic, immunohistochemical, and ploidy analysis of 23 cases. Mod Pathol 13: 900-908, 2000.

38. Khan AS, Bakhshi GD, Shaikh A, Khan AA, Khan AA and Chitale A: Extraskeletal Chondrosarcoma of Labium Majus. Case Reports in Pathology, ID, p429562, 2011.

39. Lin J, Yip KM, Maffulli N and Chow LT: Extraskeletal mesenchymal chondrosarcoma of the labium majus. Gynecol Oncol 60: 492-493, 1996.

40. Santacruz MR, Proctor L, Thomas DB and Gehrig PA: Extraskeletal myxoid chondrosarcoma: A report of a gynecologic case. Gynecol Oncol 98: 498-501, 2005.

41. Sawada M, Tochigi N, Sasajima Y, Hasegawa T, Kasamatsu T and Kitawaki J: Primary extraskeletal myxoid chondrosarcoma of the vulva. J Obstet Gynaecol Res 37: 1706-1710, 2011.